$297 Million is the total value of INTERNATIONAL BIOTECHNOLOGY TRUST PLC's 65 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 27.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AMGN | Sell | AMGEN INC COM | $21,297,363 | -18.2% | 79,246 | -32.4% | 7.18% | -9.4% |
| SUPN | Sell | SUPERNUS PHARMACEUTICALS | $11,754,340 | -25.3% | 426,500 | -18.5% | 3.96% | -17.3% |
| VERA | Sell | VERA THERAPEUTICScl a | $10,381,880 | -33.6% | 758,355 | -22.2% | 3.50% | -26.6% |
| HRMY | Sell | Harmony Biosciences Holdi | $10,306,165 | -48.6% | 314,500 | -44.9% | 3.47% | -43.2% |
| MRTX | Sell | MIRATI THERAPEUTICS INC C | $9,404,640 | +0.1% | 216,000 | -16.9% | 3.17% | +10.8% |
| UTHR | Sell | UNITED THERAPEUTICS CORP | $7,657,755 | -34.3% | 33,959 | -35.6% | 2.58% | -27.2% |
| REGN | Sell | REGENERON PHARMACEUTICALS | $7,278,338 | -62.5% | 8,847 | -67.2% | 2.45% | -58.5% |
| ALNY | Sell | ALNYLAM PHARMACEUTICALS I | $6,517,280 | -58.0% | 36,800 | -54.9% | 2.20% | -53.5% |
| NBIX | Sell | NEUROCRINE BIOSCIENCES IN | $3,247,219 | -50.0% | 28,877 | -58.1% | 1.09% | -44.6% |
| DNLI | Sell | DENALI THERAPEUTICS INC C | $3,172,400 | -42.7% | 154,000 | -18.1% | 1.07% | -36.6% |
| HALO | Sell | HALOZYME THERAPEUTICS INC | $2,376,040 | -31.0% | 62,200 | -34.9% | 0.80% | -23.7% |
| DYN | Sell | DYNE THERAPEUTICS INC COM | $1,231,494 | -63.6% | 137,751 | -54.2% | 0.42% | -59.7% |
| AKRO | Sell | AKERO THERAPEUTICS INC CO | $935,174 | -74.5% | 18,489 | -76.4% | 0.32% | -71.7% |
| HCM | Exit | HUTCHMED CHINA LTDsponsored ads | $0 | – | -68,000 | -100.0% | -0.25% | – |
| SAGE | Exit | SAGE THERAPEUTICS INC | $0 | – | -20,000 | -100.0% | -0.29% | – |
| TVTX | Exit | TRAVERE THERAPEUTICS INC | $0 | – | -441,019 | -100.0% | -2.06% | – |
| HZNP | Exit | HORIZON THERAPEUTICS | $0 | – | -67,000 | -100.0% | -2.10% | – |
| APLS | Exit | APELLIS PHARMS. | $0 | – | -129,700 | -100.0% | -3.60% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GILEAD SCIENCES INC COMMO | 28 | Q3 2023 | 9.3% |
| INCYTE CORP INC COM | 28 | Q3 2023 | 7.9% |
| BIOMARIN PHARMACEUTICALS INC | 28 | Q3 2023 | 7.5% |
| REGENERON PHARMS. | 27 | Q3 2023 | 9.0% |
| BIOGEN INC COMMON STOCK | 26 | Q3 2023 | 8.7% |
| VERTEX PHARMS. | 25 | Q3 2023 | 8.4% |
| AMGEN INC COM | 25 | Q3 2023 | 7.9% |
| NEUROCRINE BIOSCIENCES INC | 25 | Q3 2023 | 6.9% |
| ALYNYLAM PHARMACEUTICALS INC | 25 | Q3 2023 | 6.7% |
| IONIS PHARMS. | 25 | Q3 2023 | 4.0% |
View INTERNATIONAL BIOTECHNOLOGY TRUST PLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Altus Pharmaceuticals Inc. | February 12, 2009 | ? | ? |
| MICROMET, INC. | February 14, 2008 | 1,907,390 | 4.7% |
| EPIMMUNE INC | February 15, 2005 | 1,279,659 | 8.0% |
| ESSENTIAL THERAPEUTICS INC | April 29, 2003 | 2,500,000 | 11.7% |
| TARGETED GENETICS CORP /WA/ | April 18, 2003 | ? | ? |
| ESSENTIAL THERAPEUTICS INC | November 05, 2001 | 11 | 13.0% |
| ONYX PHARMACEUTICALS INC | October 15, 2001 | 11 | 13.0% |
| CORVAS INTERNATIONAL INC | October 12, 2001 | 11 | 13.0% |
| RIBOZYME PHARMACEUTICALS INC | October 05, 2001 | 11 | 13.0% |
View INTERNATIONAL BIOTECHNOLOGY TRUST PLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-08 |
| 13F-HR | 2023-05-18 |
| 13F-HR | 2023-02-01 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-20 |
| 13F-HR | 2022-02-15 |
| 13F-HR | 2021-11-12 |
| 13F-HR | 2021-08-11 |
View INTERNATIONAL BIOTECHNOLOGY TRUST PLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.